Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5965 tablets in paroxysmal nocturnal hemoglobinuria (phase II, randomized, open-label)
CTR20232816Phase 2Completed
- Sponsor
- Chengdu Shengdi
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-5965 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Chengdu Shengdi. Started Sep 2023; status: completed.
02
Drugs
HRS-5965
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20232816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232816.